Redmile Group

Founded 2007

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 107
Average round size
info
The average size of a deal this fund participated in
$84M
Portfolio companies 97
Rounds per year 7.64
Lead investments 17
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.21
Exits 56
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

In 2007 was created Redmile Group, which is appeared as VC. The leading representative office of defined VC is situated in the San Francisco. The venture was found in North America in United States.

Among the most popular fund investment industries, there are Pharmaceutical, Biotechnology. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Audentes Therapeutics, Foundation Medicine, Afferent Pharmaceuticals Besides, a startup needs to be aged 4-5 years to get the investment from the fund.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Redmile Group, startups are often financed by MPM Capital, Third Rock Ventures, Versant Ventures. The meaningful sponsors for the fund in investment in the same round are Fidelity Management and Research Company, Samsara BioCapital, Rock Springs Capital. In the next rounds fund is usually obtained by Deerfield, Wild Basin Investments, Three Leaf Ventures.

Deals in the range of 50 - 100 millions dollars are the general things for fund. The fund is constantly included in 7-12 investment rounds annually. This Redmile Group works on 19 percentage points more the average amount of lead investments comparing to the other organizations. When the investment is from Redmile Group the average startup value is 100-500 millions dollars. The high activity for fund was in 2019. Speaking about the real fund results, this VC is 8 percentage points more often commits exit comparing to other organizations. The higher amount of exits for fund were in 2019.

Besides them, we counted 4 critical employees of this fund in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Redmile Group:
Typical Co-investors
Redmile Group is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Redmile Group:

Funds with similar focus

Funds from United States, San Francisco
Funds with similar focus located in United States, San Francisco:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
ArpexCapital Brazil, Sao Paulo
Nine Four Ventures United States, Chicago
MkII Ventures United States, San Francisco
FINANCIERE FONDS PRIVES France, Paris
Benson Oak Ventures Israel, Herzliya
AIMCo United States, Denver
EDINA -
Natixis France, Paris
Cnfol.com China, Fuzhou
TPP Capital Advisors Japan, Tokyo
Sumeru Equity Partners United States, Foster City
Lumis Partners United States, Stamford
Telluride Venture Fund -
VOYAGE GROUP Japan, Chiyoda
Zhangjiagang Dagangcheng China, Zhangjiagang
Hongshi Capital Management China, Beijing
Harvest Partners United States, New York
Guangdong Xiaozhong Touzi China, Zhuhai
Indigo Partners United States, Phoenix
OCT China, Xiamen

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Zentera Therapeutics

Biotechnology
Pharmaceutical
1
$75M04 Aug 2021 China, Shanghai

Thriveworks

Health Care
Therapeutics
n/a
26 Jul 2021 United States, Lynchburg

Prime Medicine

Biotechnology
Medical
1
$200M13 Jul 2021 United States, Cambridge

Strand Therapeutics

Biotechnology
Therapeutics
1
$52M23 Jun 2021 United States, Cambridge

Mnemo Therapeutics

Biotechnology
1
$88M16 Jun 2021 France, Paris

Clear Labs

Biotechnology
Health Diagnostics
Robotics
Software
1
$60M26 May 2021 United States, " United States"}

HydraFacial

Beauty
Health Care
Manufacturing
Medical Device
n/a
$350M06 May 2021 United States, Long Beach

Ceribell

Biotechnology
Health Care
Health Diagnostics
Medical Device
1
$53M29 Apr 2021 United States, Mountain View

Biotechnology
Health Care
Life Science
Therapeutics
1
$105M28 Apr 2021 United States, San Diego
News
Zentera Therapeutics Raises $75M in Series b Funding

– Zentera Therapeutics, a Shanghai, China-based clinical-stage biopharmaceutical company, raised $75M in Series B funding.
– The round was led by OrbiMed Advisors Asia and Tybourne Capital Management with participation from Avidity Partners, Casdin Capital, Surveyor Capital, Farallon Capital Management, Lilly Asia Ventures, Logos Capital, Perceptive Advisors, Redmile Group and Viking Global Investors.
– The company intends to use the funds to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China.

Prime Medicine Raises $315M in Funding

– Prime Medicine is a Cambridge MA-based biotechnology company developing gene editing technology.
– The company raised $115M in Series A funding and $200M in Series B funding.
– The Series A round was led by ARCH Venture Partners with participation from F-Prime Capital, GV, and Newpath Partners.
– The Series B included all Series A investors, plus Casdin Capital with participation from Cormorant Asset Management, Moore Strategic Ventures, Public Sector Pension Investment Board, Redmile Group and Samsara BioCapital.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Redmile Group?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: